Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety, Tolerability and Efficacy Study of a Caspase Inhibitor, IDN-6556, in Patients Undergoing Orthotopic Liver Transplantation (OLT)

NCT00080236 is registered in ClinicalTrials.gov with Conatus Pharmaceuticals Inc. as lead sponsor.

NCT NCT00080236
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00080236 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety, Tolerability and Efficacy Study of a Caspase Inhibitor, IDN-6556, in Patients Undergoing Orthotopic Liver Transplantation (OLT)
Lead sponsor
Conatus Pharmaceuticals Inc.
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2003
Completion date
January 31, 2006
Enrollment
99 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, hepatocellular, cholestasis, hepatitis, liver transplantation